alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 106 (Thursday, June 4, 2009)]
[Rules and Regulations]
[Page 26782]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-13015]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524

[Docket No. FDA-2009-N-0665]


Ophthalmic and Topical Dosage Form New Animal Drugs; Change of 
Sponsor; Diclofenac; Ivermectin Otic Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect a change of sponsor for diclofenac sodium 
cream and ivermectin otic suspension from IDEXX Pharmaceuticals, Inc., 
to Boehringer Ingelheim Vetmedica, Inc.

DATES: This rule is effective June 4, 2009.

FOR FURTHER INFORMATION CONTACT:  David R. Newkirk, Center for 
Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail: 
<a href="/cdn-cgi/l/email-protection#e58184938c81cb8b80928e8c978ea5838184cb8d8d96cb828a93"><span class="__cf_email__" data-cfemail="731712051a175d1d1604181a0118331517125d1b1b005d141c05">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: IDEXX Pharmaceuticals, Inc., 7009 Albert 
Pick Rd., Greensboro, NC 27409, has informed FDA that it has 
transferred ownership of, and all rights and interest in, NADA 141-186 
for SURPASS (diclofenac sodium) topical cream and NADA 141-174 for 
ACAREXX (ivermectin) otic suspension to Boehringer Ingelheim Vetmedica, 
Inc., 2621 North Belt Highway, St. Joseph, MO 64506-2002. Accordingly, 
the regulations are amended in 21 CFR 524.590 and 524.1195 to reflect 
the change of sponsorship.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 524

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is 
amended as follows:

PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 524 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec.  524.590  [Amended]

0
2. In paragraph (b) of Sec.  524.590, remove ``065274'' and in its 
place add ``000010''.


Sec.  524.1195  [Amended]

0
3. In paragraph (b) of Sec.  524.1195, remove ``065274'' and in its 
place add ``000010''.

    Dated: May 27, 2009.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. E9-13015 Filed 6-3-09; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
* Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED December 6, 2006 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 06-41031 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus JUAN CARLOS ALONSO-MARTINEZ, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Southern District of Texas USDC No. 2:06-CR-136-1

-------------------- Before REAVLEY, STEWART, and CLEMENT, Circuit Judges.
PER CURIAM: * Appealing the Judgment in a Criminal Case, Juan Carlos Alonso-Martinez raises arguments that are foreclosed by Almendarez-Torres v. United States , 523 U.S. 224, 235 (1998), which held that 8 U.S.C. § 1326(b)(2) is a penalty provision and not a separate criminal offense. The Government’s motion for summary affirmance is GRANTED, and the judgment of the district court is AFFIRMED.
##### 



Exhibit 99.3

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Thornburg Mortgage, Inc. (the
Company) on Form 10-K for the period ending December 31, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the Report), I,
Richard P. Story, Executive Vice President, Chief Financial Officer and
Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

/s/ Richard P. Story

Richard P. Story
Executive Vice President, Chief Financial Officer and Treasurer
March 20, 2003
II 

111TH CONGRESS 

1ST SESSION S. 2680 

To extend temporarily the suspension of duty on Butralin. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. BURR introduced the following bill; which was read twice and referred to 

the Committee on Finance 

A BILL 

To extend temporarily the suspension of duty on Butralin. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. BUTRALIN. 

4 (a) IN GENERAL.—Heading 9902.12.01 of the Har5 monized Tariff Schedule of the United States (relating to 

6 Butralin) is amended by striking the date in the effective 

7 column period and inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 

10 warehouse for consumption, on or after the 15th day after 

11 the date of the enactment of this Act. 

Æ 


hsrobinson on DSK69SOYB1PROD with BILLS
June 22, 1998



Rabar Market Research
10 Bank St. - Suite 830
White Plain, N.Y. 10606

Attention:  Mr. John Dreyer
                    Mr. Paul Rabar

         Re:      Management Agreement Renewal
                  F-1000 Futures Fund L.P., Series IX

Dear Mr. Dreyer & Mr. Rabar:

We are  writing  with  respect  to  your  management  agreement  concerning  the
commodity pool to which reference is made above (the "Management Agreement"). We
would like to extend the term of the Management  Agreement through June 30, 1999
and make the attached  modification  on Rider 1. The  incentive  fee will now be
paid annually  instead of  quarterly.  All other  provisions  of the  Management
Agreement will remain unchanged.

Please indicate your agreement to and acceptance of this modification by signing
one copy of this letter and returning it to the attention of Mr. Daniel Dantuono
at the address above or fax to 212-723-8985.  If you have any questions I can be
reached at 212-723-5416.

Very truly yours,

SMITH BARNEY FUTURES MANAGEMENT INC.



By:
         Daniel A. Dantuono
         Chief Financial Officer,
         Director & Treasurer

AGREED AND ACCEPTED

RABAR MARKET RESEARCH

By:

Print Name:

DAD/sr
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                          0000823187 
<NAME>                          ACL            ACL 
       
<S>                             <C>            <C>
<PERIOD-TYPE>                  3-MOS           6-MOS
<FISCAL-YEAR-END>             DEC-31-1997     DEC-31-1997
<PERIOD-START>                JAN-1-1997      APR-1-1997
<PERIOD-END>                  MAR-31-1997     JUN-30-1997
<CASH>                         0                 314,548
<SECURITIES>                   0                 0
<RECEIVABLES>                  1,004,876         624,543
<ALLOWANCES>                     339,349         319,672
<INVENTORY>                      544,950         338,453
<CURRENT-ASSETS>               1,356,006         979,615
<PP&E>                         1,399,181       1,304,439
<DEPRECIATION>                   940,365         932,880
<TOTAL-ASSETS>                 1,814,822       1,351,174
<CURRENT-LIABILITIES>          4,970,067       1,332,777
<BONDS>                        0               0
<PREFERRED-MANDATORY>          0               0
<PREFERRED>                    0               4,897,429
<COMMON>                       231,298         418,898
<OTHER-SE>                     (328,000)       (335,000)
<TOTAL-LIABILITY-AND-EQUITY>   1,814,822       1,351,174
<SALES>                        1,875,031         856,722
<TOTAL-REVENUES>               1,875,031         856,722
<CGS>                          1,458,271         488,266
<TOTAL-COSTS>                    683,458         626,778
<OTHER-EXPENSES>               0               0
<LOSS-PROVISION>               0               0
<INTEREST-EXPENSE>             (232,347)       (139,907)
<INCOME-PRETAX>                (483,961)       (305,995)
<INCOME-TAX>                   0               0
<INCOME-CONTINUING>            (483,961)       (305,995)
<DISCONTINUED>                 0                (58,082)
<EXTRAORDINARY>                0               0
<CHANGES>                      0               0
<NET-INCOME>                   (483,961)       (364,077)
<EPS-PRIMARY>                  ($0.12)         ($0.07)
<EPS-DILUTED>                  0               0
        


</TABLE>
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER DENYING MOTION FOR REHEARING

Appellate case name: In re TIC Philly Lansdale 2, LLC, TIC Philly Lansdale 3, LLC, TIC 

Philly Lansdale 4, LLC, TIC Philly Lansdale 5, LLC, TIC Philly 

Lansdale 6, LLC, TIC Philly Lansdale 7, LLC, TIC Philly Lansdale 8, 

LLC, TIC Philly Lansdale 9, LLC, TIC Philly Lansdale 10, LLC, TIC 

Philly Lansdale 11, LLC, TIC Philly Lansdale 13, LLC, TIC Philly 

Lansdale 14, LLC, TIC Philly Lansdale 16, LLC, TIC Philly Lansdale 

18, LLC, TIC Philly Lansdale 19, LLC, TIC Philly Lansdale 20, LLC, 

TIC Philly Lansdale 21, LLC, TIC Philly Lansdale 23, LLC, TIC 

Philly Lansdale 24, LLC, TIC Philly Lansdale 25, LLC, TIC Philly 

Lansdale 27, LLC, TIC Philly Lansdale 29, LLC, TIC Philly Lansdale 

30, LLC, TIC Philly Lansdale 31, LLC, TIC Philly Lansdale 32, LLC, 

TIC Philly Lansdale 33, LLC, and Wayne Mar, d/b/a TIC Philly 

Lansdale H

Appellate case number: 01-22-00192-CV

Trial court case number: 2021-46723

Trial court: 151st District Court of Harris County

Date Motion filed: May 20, 2022

Party filing motion: Relator

It is ordered that Relator’s Motion for Rehearing is denied.

Judge’s signature: /s/ Julie Countiss_________

 Acting for the Court

Panel consists of Chief Justice Radack and Justices Hightower and Countiss.

Date: June 9, 2022
<PAGE>   1
 
                                                                    EXHIBIT 23.1
 
                   CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
 
     As independent public accountants, we hereby consent to the incorporation
of our report dated March 31, 1999 with respect to the consolidated financial
statements and schedule included in this Form 10-K, into the Company's
previously filed Registration Statements on Form S-8 (File No. 333-90798, File
No. 333-36086, File No. 333-55008 and File No. 333-55006), on Form S-3 (File No.
333-39939), and on Form S-2 (File No. 333-66867).
 
                                          ARTHUR ANDERSEN LLP
 
San Jose, California
   
April 15, 1999
[Federal Register Volume 74, Number 104 (Tuesday, June 2, 2009)]
[Notices]
[Page 26428]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12721]


=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Proposal Review Panel for Chemistry; Notice of Meeting

    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463, as amended), the National Science Foundation announces the 
following meeting.

    Name: Proposal Review Panel for Chemistry (1191).
    Date/Time: June 15, 2009, 5 p.m.-9 p.m.; June 16, 2009, 8:30 
a.m.-5:30 p.m.; June 17, 2009, 8:30 a.m.-1 p.m.
    Place: University of Washington, Bagley Hall, Seattle, WA 98195-
1700.
    Type of Meeting: Part-Open.
    Contact Person: Katharine Covert, National Science Foundation, 
Arlington, VA, 703-292-4950.
    Purpose of Meeting: To conduct a post award site visit 
evaluation for the Center for Enabling New Transformations through 
Catalysis (CENTC), a research center funded through the Centers for 
Chemical Innovation (CCI) Program.

Agenda:

Monday, June 15, 2009

5 p.m.-9 p.m. Closed--Executive Session.

Tuesday, June 16

8:30 a.m.-11:40 a.m. Open--Welcome, Overview of Center, Oral 
Research Presentations.
11:40 a.m.-1 p.m. Lunch.
12:30 p.m.-1 p.m. Closed Executive Session.
1 p.m.-1:50 p.m. Open--Oral Research Presentations.
1:50 p.m.-3 p.m. Open--Poster Session.
3 p.m.-5 p.m. Open--Presentations on Center Management and Impacts 
on Innovation, Education, Diversity and Outreach.
5 p.m.-5:30 p.m. Closed--Executive Session.

Wednesday, June 17

8:30 a.m.-1 p.m. Closed--Executive Session, Report Preparation.

    Reason for Closing: Topics to be discussed and evaluated during 
the site review will include information of a proprietary or 
confidential nature, including technical information; and 
information on personnel. These matters are exempt under 5 
U.S.C.552b(c), (4) and (6) of the Government in the Sunshine Act.

    Dated: May 28, 2009.
Susanne Bolton,
Committee Management Officer.
[FR Doc. E9-12721 Filed 6-1-09; 8:45 am]
BILLING CODE 7555-01-P
Skip to main content An icon that symbolizes the United States Department of Transportation logo. United States Department of Transportation
        Report a Safety Problem

  Toggle navigation
      National Highway Traffic Safety AdministrationNational Highway Traffic Safety AdministrationHomepage

    Ratings
                                Recalls
                                Risky Driving
                                Road Safety
                                Vehicle Safety
      
            More Info

                      Briefing Room
          
                        
            Importing a Vehicle
          
                                      
            
            Data
          
                        
            Research
          
                        
            Laws & Regulations
          
                    
                      Vehicle Manufacturers
                      State Governments
                      Enforcement & Justice Car Seats and Booster Seats
              
							
								Car Seat Use After a Crash


Language:
English
        Español
      Share:
  Facebook
  Twitter
  LinkedIn
  Mail




		Car Seat Use After a Crash
  
       
  NHTSA recommends that car seats be replaced following a moderate or severe crash in order to ensure a continued high level of crash protection for child passengers. Car seats do not automatically need to be replaced following a minor crash.

 
  **What defines a minor crash?**

**A minor crash is one in which ALL of the following apply:**

The vehicle was able to be driven away from the crash site.
	The vehicle door nearest the car seat was not damaged.
	None of the passengers in the vehicle sustained any injuries in the crash.
	If the vehicle has air bags, the air bags did not deploy during the crash; and
	There is no visible damage to the car seat.**NEVER** use a car seat that has been involved in a moderate to severe crash. Always follow manufacturer's instructions.
 NHTSA Information
              
              About NHTSA
          Careers & Internships
          Contact Us
          Recall Information
          Report a Safety ProblemInformation For
              
              Vehicle Manufacturers
          State Governments
          Enforcement & JusticeNHTSA Sites
              
        SaferCar App
          TrafficSafetyMarketing.gov
          EMS.gov
          911.gov
            Website Information
              
        Web Policies & Notices
          Accessibility
          FOIA
          Privacy Policy
          Information Quality
          Vulnerability Disclosure Policy
          No Fear Act Data
          Ethics
          Civil Rights
          Office of Inspector General
          OIG Hotline
          BusinessUSA
          USA.gov
          WhiteHouse.gov

            National Highway Traffic Safety AdministrationNational Highway Traffic Safety Administration
              1200 New Jersey Avenue, SE
                Washington, D.C. 20590
              888-327-4236888-275-9171 (TTY)
              Twitter
                LinkedIn
                Facebook
                Youtube
                Instagram
        Submit Feedback >
<PAGE>   1
PART I. EXHIBITS


EXHIBIT 11, STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
<TABLE>
<CAPTION>



                                                                        Three Months Ended
                                                                             March 31
                                                                  ------------------------------
                                                                       1999            1998
                                                                  --------------  --------------

<S>                                                          <C>     <C>             <C>
 Weighted average common
      shares outstanding                                     A        2,320,861       2,320,861
 Weighted average dilutive
      warrants outstanding                                                            1,172,000
 Weighted average common                                          ==============  ==============
      and dilutive shares outstanding                        B        2,320,861       3,492,861
                                                                  ==============  ==============

 Net income (loss) applicable to common stock                C      $(1,362,000)      $ 475,000
                                                                  ==============  ==============

 Basic earnings (loss) per share                            C/A         $ (0.59)         $ 0.20
                                                                  ==============  ==============

 Diluted earnings (loss) per share                          C/B         $ (0.59)         $ 0.14
                                                                  ==============  ==============
</TABLE>
Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Kaire Holdings, Inc. (the "Company")
on Form 10-QSB for the period ending March 31, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Joel G.
Rubenstein, Managing Director of the Company, certify, pursuant to 18 U.S.C.
Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002,
that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.



                              /s/ Steven Westlund
                              -----------------------------
                              Steven Westlund
                              Chief Financial Officer
                              May 20, 2003



                                     - 12 -
<PAGE>
                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Kaire Holdings, Inc(the "Company")
on Form 10-QSB for the period ending March 31, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted
pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.


                              /s/ Steven Westlund
                              -----------------------------
                              Steven Westlund
                              Chief Executive Officer
                              May 20, 2003


                                     - 13 -
<PAGE>
<TABLE> <S> <C>

<ARTICLE>                  5
       
<S>                                                  <C>
<PERIOD-TYPE>                                        12-MOS
<FISCAL-YEAR-END>                                    MAR-31-1997
<PERIOD-END>                                         MAR-31-1997
<CASH>                                               373,729
<SECURITIES>                                         3,240,944
<RECEIVABLES>                                        000
<ALLOWANCES>                                         000
<INVENTORY>                                          000
<CURRENT-ASSETS>                                     000
<PP&E>                                               000
<DEPRECIATION>                                       000
<TOTAL-ASSETS>                                       35,694,649<F1>
<CURRENT-LIABILITIES>                                000
<BONDS>                                              000
<PREFERRED-MANDATORY>                                000
<PREFERRED>                                          000
<COMMON>                                             000
<OTHER-SE>                                           35,355,327
<TOTAL-LIABILITY-AND-EQUITY>                       35,694,649<F2>
<SALES>                                              000
<TOTAL-REVENUES>                                     400,349<F3>
<CGS>                                                000
<TOTAL-COSTS>                                        000
<OTHER-EXPENSES>                                     563,610<F4>
<LOSS-PROVISION>                                     000
<INTEREST-EXPENSE>                                   000
<INCOME-PRETAX>                                      000
<INCOME-TAX>                                         000
<INCOME-CONTINUING>                                  000
<DISCONTINUED>                                       000
<EXTRAORDINARY>                                      000
<CHANGES>                                            000
<NET-INCOME>                                         (3,131,087)<F5>
<EPS-PRIMARY>                                        (60.86)
<EPS-DILUTED>                                        000
<FN>
<F1>Included  in total assets are  Investments in Local Limited  Partnerships of
$31,792,098,  Restricted cash of $239,155,  Organizational  costs, net of $9,167
and Other assets of $39,556.  <F2>Included  in total  liabilities and equity are
Accounts  payable to  affiliates  of $304,382 and  Accounts  payable and accrued
expenses of $34,940.
<F3>Total revenue includes Investment of $223,158 and Other of $177,191.
<F4>Included in Other Expenses are Asset  Management  fees of $277,575,  General
and  Administrative  of  $240,204,  and  Amortization  of $45,831.  <F5>Net loss
reflects Equity in losses of Local Limited Partnerships of $2,967,826.
</FN>
        

</TABLE>